

Fabien DESPAS - Publications 2015-2019

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales

Mise à jour juillet 2019

2019

1. De Barros S, Vayr F, **Despas F**, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, Laurent G, Hugué F, Herin F. [The impact of chronic myeloid leukemia on employment: the French prospective study](#). Ann Hematol. 2019 Mar;98(3):615-623. doi: 10.1007/s00277-018-3549-5.
2. **Despas F**, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Montastruc F, Bagheri H, Montastruc JL. [Are Lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study](#). Fundam Clin Pharmacol. 2019 Jun 28. doi: 10.1111/fcp.12496. [Epub ahead of print]
3. Montastruc JL, Benevent J, Montastruc F, Bagheri H, **Despas F**, Lapeyre-Mestre M, Sommet A. [What is pharmacoepidemiology? Definition, methods, interest and clinical applications](#). Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001.

2018

1. Conte C, Palmaro A, Grosclaude P, Daubisse-Marliac L, **Despas F**, Lapeyre-Mestre M. [A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases](#). Medicine (Baltimore). 2018 Jan;97(2):e9418. doi: 10.1097/MD.00000000000009418.
2. Mahé J, de Campaigno EP, Chené AL, Montastruc JL, **Despas F**, Jolliet P. [Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from VigiBase®](#). Br J Clin Pharmacol. 2018 Oct;84(10):2373-2383. doi: 10.1111/bcp.13693.
3. Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, **Despas F**. [Correction to: Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase](#). Drug Saf. 2018 Aug;41(8):827. doi: 10.1007/s40264-018-0672-0.
4. Rioufol C, Lamy S, Conte C, Jeanneau P, Compaci G, Delpierre C, Lapeyre-Mestre M, Laurent G, **Despas F**. [Non-cancer drug consumption during the early trajectory of lymphoma survivorship](#). Therapie. 2018 Sep;73(4):307-317. doi: 10.1016/j.therap.2017.10.007.
5. Schmidt EA, **Despas F**, Pavy-Le Traon A, Czosnyka Z, Pickard JD, Rahmouni K, Pathak A, Senard JM. [Intracranial Pressure Is a Determinant of Sympathetic Activity](#). Front Physiol. 2018 Feb 8;9:11. doi: 10.3389/fphys.2018.00011.
6. Vaysse C, Chantalat E, Beyne-Rauzy O, Morineau L, **Despas F**, Bachaud JM, Caunes N, Poublanc M, Serrano E, Bugat R, Rougé Bugat ME, Fize AL. [The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation](#). JMIR Med Educ. 2018 Mar 5;4(1):e6. doi: 10.2196/mededu.9185.

2017

1. Boudou N, **Despas F**, Rothem JV, Lairez O, Elbaz M, Vaccaro A, Lebrin M, Pathak A, Carrié D. [Direct evidence of sympathetic hyperactivity in patients with vasospastic angina](#). Am J Cardiovasc Dis. 2017 Jun 15;7(3):83-88.
2. de Campaigno EP, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, **Despas F**. [Identification of Cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining Pharmacovigilance and Pharmacodynamics](#). Br J Clin Pharmacol. 2017 Jul;83(7):1544-1555. doi: 10.1111/bcp.13238.
3. de Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, **Despas F**. [Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase](#). Drug Saf. 2017 Dec;40(12):1249-1258. doi: 10.1007/s40264-017-0575-5.
4. Palmaro A, Gauthier M, Conte C, Grosclaude P, **Despas F**, Lapeyre-Mestre M. [Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry](#). Medicine (Baltimore). 2017 Mar;96(12):e6189. doi: 10.1097/MD.0000000000006189.
5. Palmaro A, Gauthier M, **Despas F**, Lapeyre-Mestre M. [Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients](#). Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1492-1499. doi: 10.1002/pds.4266.
6. Palmaro A, Rougé-Bugat ME, Gauthier M, **Despas F**, Moulis G, Lapeyre-Mestre M. [Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database](#). Pharmacoepidemiol Drug Saf. 2017 May;26(5):578-586. doi: 10.1002/pds.4180.
7. Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, **Despas F**. [Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics](#). Br J Clin Pharmacol. 2017 Jul;83(7):1544-1555. doi: 10.1111/bcp.13238.

2016

1. Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, **Despas F**, Pathak A, Montastruc JL. [Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy](#). Target Oncol. 2016 Aug;11(4):549-52. doi: 10.1007/s11523-016-0417-x.
2. Bondon-Guitton E, **Despas F**, Becquemont L. [The contribution of pharmacogenetics to pharmacovigilance](#). Therapie. 2016 Apr;71(2):223-8. doi: 10.1016/j.therap.2016.02.005.
3. Conte C, Rueter M, Laurent G, Bourrel R, Lapeyre-Mestre M, **Despas F**. [Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin's lymphoma: a cohort study of the French national health insurance database](#). Support Care Cancer. 2016 Nov;24(11):4791-9. doi: 10.1007/s00520-016-3331-y.
4. Lamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, **Despas F**, Laurent G, Delpierre C. [The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study](#). BMC Health Serv Res. 2016 Aug 2;16(a):336. doi: 10.1186/s12913-016-1553-9.

5. Palmaro A, Moulis G, **Despas F**, Dupouy J, Lapeyre-Mestre M. [Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies](#). *Fundam Clin Pharmacol*. 2016 Jun 28. doi: 10.1111/fcp.12214.
6. Récoché I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, **Despas F**, Montastruc JL, Bondon-Guitton E. [Drug-drug interactions with imatinib: An observational study](#). *Medicine (Baltimore)*. 2016 Oct;95(40):e5076.
7. Tournaire G, **Despas F**, Huguet F, Montastruc JL, Bondon-Guitton E. [Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report](#). *J Clin Pharm Ther*. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383.
8. Tranchard F, Hein C, Lacombe J, Villars H, Montastruc JL, **Despas F**. [Medication errors and look-alike tablets: the splitting issue](#). *Pharmacoepidemiol Drug Saf*. 2016 Jul 14. doi: 10.1002/pds.4063.

2015

1. Bellot M, Galandrin S, Boularan C, Matthies HJ, **Despas F**, Denis C, Javitch J, Mazères S, Sanni SJ, Pons V, Seguelas MH, Hansen JL, Pathak A, Galli A, Sénard JM, Galés C. [Dual agonist occupancy of AT1-R- \$\alpha\$ 2C-AR heterodimers results in atypical Gs-PKA signaling](#). *Nat Chem Biol*. 2015 Apr;11(4):271-9. doi: 10.1038/nchembio.1766.
2. Borel C, Lamy S, Compaci G, Récher C, Jeanneau P, Nogaro JC, Bauvin E, **Despas F**, Delpierre C, Laurent G. [A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival](#). *BMC Cancer*. 2015 Apr 15;15:288. doi: 10.1186/s12885-015-1287-9.
3. Compaci G, Rueter M, Lamy S, Oberic L, Recher C, Lapeyre-Mestre M, Laurent G, **Despas F**. [Ambulatory Medical Assistance--After Cancer \(AMA-AC\): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy](#). *BMC Cancer*. 2015 Oct 24;15:781. doi: 10.1186/s12885-015-1815-7.
4. Pathak A, Coleman L, Roth A, Stanley J, Bailey L, Markham P, Ewen S, Morel C, **Despas F**, Honton B, Senard JM, Fajadet J, Mahfoud F. [Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity](#). *EuroIntervention*. 2015 Aug;11(4):477-84. doi: 10.4244/EIJV11I4A96.